A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Inclusion Criteria:

• Have a body mass index (BMI) of ≥30 kilogram/square meter (kg/m²) and ≤40 kg/m²

• Willing to learn how to self-inject study intervention (visually impaired personswho are not able to perform the injections must have the assistance of a sightedindividual trained to inject the study intervention; persons with physicallimitations who are not able to perform the injections must have the assistance ofan individual trained to inject the study intervention)

• Male or female contraceptive use by participant should be consistent with localregulations regarding the methods of contraception for those participating inclinical studies.

Exclusion Criteria:

• Have a history of diabetes mellitus, including Type 1 Diabetes Mellitus (T1DM) orType 2 Diabetes Mellitus (T2DM), history of ketoacidosis, or hyperosmolar state/coma

• Have a self-reported change (increase or decrease) in body weight >5 kilogram (kg)within 3 months prior to screening

• Have a family or personal history of medullary thyroid carcinoma (MTC) or multipleendocrine neoplasia (MEN) syndrome type 2

• Have acute or chronic hepatitis

• Have a history of an active or untreated malignancy or are in remission from aclinically significant malignancy for less than 5 years